Drug intelligence / Profile preview

washed fecal microbiota

Development stage
Phase 3
Lead developer
Second Affiliated Hospital of Nanjing Medical University
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Cell Therapies, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral, Rectal, Endoscopic
01

Overview

Washed fecal microbiota (WFM) is a refined microbial suspension derived from healthy donor stool through a standardized, automated purification process. Developed primarily by researchers at the Second Affiliated Hospital of Nanjing Medical University, the preparation involves multiple rounds of washing and centrifugation (often using the GenFMTer system) to remove non-bacterial components such as pro-inflammatory cytokines, metabolites (e.g., leukotrienes, complement), and food debris found in traditional crude fecal microbiota transplants (FMT). By isolating the bacterial fraction, WFM aims to reduce the incidence of acute adverse events, such as fever and abdominal pain, while maintaining therapeutic efficacy. Its mechanism of action involves restoring intestinal microbial diversity, competitive exclusion of enteric pathogens like *Clostridioides difficile*, and modulating the host immune system by inducing regulatory T cells and reducing pro-inflammatory signaling. It is extensively investigated for inflammatory bowel disease (IBD), functional gastrointestinal disorders, and various extra-intestinal conditions linked to gut dysbiosis.

Other names
washed microbiotapurified fecal microbiota

Beyond the preview

Go deeper on washed fecal microbiota.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on washed fecal microbiota.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call